Literature DB >> 12473110

Transcriptional activity of interferon regulatory factor (IRF)-3 depends on multiple protein-protein interactions.

Hongmei Yang1, Charles H Lin, Gang Ma, Melissa Orr, Michael O Baffi, Marc G Wathelet.   

Abstract

Virus infection results in the activation of a set of cellular genes involved in host antiviral defense. IRF-3 has been identified as a critical transcription factor in this process. The activation mechanism of IRF-3 is not fully elucidated, yet it involves a conformational change triggered by the virus-dependent phosphorylation of its C-terminus. This conformational change leads to nuclear accumulation, DNA binding and transcriptional transactivation. Here we show that two distinct sets of Ser/Thr residues of IRF-3, on phosphorylation, synergize functionally to achieve maximal activation. Remarkably, we find that activated IRF-3 lacks transcriptional activity, but activates transcription entirely through the recruitment of the p300/CBP coactivators. Moreover, we show that two separate domains of IRF-3 interact with several distinct regions of p300/CBP. Interference with any of these interactions leads to a complete loss of transcriptional activity, suggesting that a bivalent interaction is essential for coactivator recruitment by IRF-3.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473110     DOI: 10.1046/j.1432-1033.2002.03330.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  19 in total

1.  Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit.

Authors:  Shunbin Ning; Leslie E Huye; Joseph S Pagano
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

2.  Human rhinovirus attenuates the type I interferon response by disrupting activation of interferon regulatory factor 3.

Authors:  Tao Peng; Swathi Kotla; Roger E Bumgarner; Kurt E Gustin
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Recruitment of activated IRF-3 and CBP/p300 to herpes simplex virus ICP0 nuclear foci: Potential role in blocking IFN-beta induction.

Authors:  Gregory T Melroe; Lindsey Silva; Priscilla A Schaffer; David M Knipe
Journal:  Virology       Date:  2006-11-28       Impact factor: 3.616

4.  Mitogen-activated protein kinase-mediated licensing of interferon regulatory factor 3/7 reinforces the cell response to virus.

Authors:  Sonja Schmid; David Sachs; Benjamin R tenOever
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

5.  Dengue virus subverts the interferon induction pathway via NS2B/3 protease-IκB kinase epsilon interaction.

Authors:  Yesseinia I Angleró-Rodríguez; Petraleigh Pantoja; Carlos A Sariol
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

6.  A Rhesus Rhadinovirus Viral Interferon (IFN) Regulatory Factor Is Virion Associated and Inhibits the Early IFN Antiviral Response.

Authors:  Gabriela Morin; Bridget A Robinson; Kelsey S Rogers; Scott W Wong
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

7.  Interferon regulatory factor 3-CL, an isoform of IRF3, antagonizes activity of IRF3.

Authors:  Chunhua Li; Lixin Ma; Xinwen Chen
Journal:  Cell Mol Immunol       Date:  2010-12-06       Impact factor: 11.530

8.  Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain.

Authors:  Marc G Wathelet; Melissa Orr; Matthew B Frieman; Ralph S Baric
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  Phosphorylation of IRF-3 on Ser 339 generates a hyperactive form of IRF-3 through regulation of dimerization and CBP association.

Authors:  Jean-François Clément; Annie Bibeau-Poirier; Simon-Pierre Gravel; Nathalie Grandvaux; Eric Bonneil; Pierre Thibault; Sylvain Meloche; Marc J Servant
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

10.  Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-beta production.

Authors:  Sotiria Tzima; Panayiotis Victoratos; Ksanthi Kranidioti; Maria Alexiou; George Kollias
Journal:  J Exp Med       Date:  2009-04-27       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.